drugset / Trial / NCT06331832
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Summary
Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imvotamab | Monoclonal antibody | — | — |